Vicapsys Life Sciences Inc

$ Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000149315224041809 Filed on October 21, 2024

Income Statement

Concept	2024 Q3	2023 Q4	2023

Balance Sheet

Concept	2024 Q3	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$9.422K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses		$30.23K
Receivables
Other Receivables
Total Short-Term Assets		$39.66K
YoY Change		-44.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets		$39.66K
Total Long-Term Assets		$0.00
Total Assets		$39.66K
YoY Change		-44.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$537.4K
YoY Change		-15.39%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$18.71K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$1.968M
YoY Change		92.44%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$1.968M
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings		-$16.30M
YoY Change		7.82%
Common Stock		$32.07K
YoY Change		2.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$1.929M
YoY Change
Total Liabilities & Shareholders Equity		$39.66K
YoY Change		-44.94%

Cashflow Statement

Concept	2024 Q3	2023 Q4	2023

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001468639
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q4	VICP	Common Stock To Be Issued CommonStockToBeIssued		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2022	VICP	Financing Costs FinancingCosts		usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2022	VICP	Stock Issued During Period Value Issuance For Common Stock To Be Issued StockIssuedDuringPeriodValueIssuanceForCommonStockToBeIssued		usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings		usd
CY2023	VICP	Stock Issued During Period Value Issuance For Common Stock To Be Issued StockIssuedDuringPeriodValueIssuanceForCommonStockToBeIssued		usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2023	VICP	Stock Issued During Period Value Common Stock To Be Issued Pursuant To Private Placement One StockIssuedDuringPeriodValueCommonStockToBeIssuedPursuantToPrivatePlacementOne		usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization		usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
CY2022	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	VICP	Deferred Offering Costs In Accounts Payable DeferredOfferingCostsInAccountsPayable		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022Q4	VICP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber		shares
CY2022Q4	VICP	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-56145
CY2023	dei	Entity Registrant Name EntityRegistrantName	VICAPSYS LIFE SCIENCES, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	91-1930691
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7778 Mcginnis Ferry Rd. #270
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Suwanee
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30024
CY2023	dei	City Area Code CityAreaCode	(972)
CY2023	dei	Local Phone Number LocalPhoneNumber	891-8033
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Public Float EntityPublicFloat	4658159	usd
CY2023	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32071299	shares
CY2023	VICP	No Insider Trading Flag NoInsiderTradingFlag	true
CY2023	dei	Auditor Firm AuditorFirmId	4048
CY2023	dei	Auditor Name AuditorName	Assurance Dimensions
CY2023	dei	Auditor Location AuditorLocation	Coral Springs, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9422	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14097	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	30234	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7483	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	50441	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	39656	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	72021	usd
CY2023Q4	us-gaap	Assets Assets	39656	usd
CY2022Q4	us-gaap	Assets Assets	72021	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	961708	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	635183	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	537449	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	272317	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	115312	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	115312	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	18712	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	335156	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1968337	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1022812	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32071299	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32071299	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31188460	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31188460	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	32071	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	31188	usd
CY2023Q4	VICP	Common Stock To Be Issued Par Or Stated Value Per Share CommonStockToBeIssuedParOrStatedValuePerShare	0.001
CY2022Q4	VICP	Common Stock To Be Issued Par Or Stated Value Per Share CommonStockToBeIssuedParOrStatedValuePerShare	0.001
CY2023Q4	VICP	Common Stock To Be Issued Shares Outstanding CommonStockToBeIssuedSharesOutstanding	0	shares
CY2022Q4	VICP	Common Stock To Be Issued Shares Outstanding CommonStockToBeIssuedSharesOutstanding	727281	shares
CY2022Q4	VICP	Common Stock To Be Issued CommonStockToBeIssued	727	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14339323	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14135257	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16300075	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15117963	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1928681	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-950791	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39656	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72021	usd
CY2023	VICP	Personnel Costs PersonnelCosts	262625	usd
CY2022	VICP	Personnel Costs PersonnelCosts	122458	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15267	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13097	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	672655	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	448806	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	340231	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	96431	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60198	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1046978	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	984790	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1046978	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-984790	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	19969	usd
CY2023	VICP	Financing Costs FinancingCosts	115165	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-135134	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1182112	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-984790	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1182112	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-984790	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	3548	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1182112	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-988338	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34548676	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34548676	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30577988	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30577988	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-121651	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	50000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	105650	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-984790	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-950791	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-950791	usd
CY2023	VICP	Stock Issued During Period Value Common Stock To Be Issued Pursuant To Private Placement StockIssuedDuringPeriodValueCommonStockToBeIssuedPursuantToPrivatePlacement	100000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	83526	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20697	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1182112	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1928681	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1928681	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1182112	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-984790	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	31289	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	340231	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	20697	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	105650	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	115082	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-37152	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1985	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	326525	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	111951	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	265132	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	159457	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-417524	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-238197	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	50000	usd
CY2023	VICP	Proceeds From Deferred Offering Costs ProceedsFromDeferredOfferingCosts	50441	usd
CY2022	VICP	Proceeds From Deferred Offering Costs ProceedsFromDeferredOfferingCosts	-15001	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-41192	usd
CY2023	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	303600	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	412849	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34999	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4675	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-203198	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14097	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	217295	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9422	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14097	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	19969	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	545	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	83526	usd
CY2022	VICP	Deferred Offering Costs In Accounts Payable DeferredOfferingCostsInAccountsPayable	35440	usd
CY2017Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	effected a 1-for-100 reverse stock split of its outstanding common stock
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1182112	usd
CY2023Q4	VICP	Working Capital Deficit WorkingCapitalDeficit	1928682	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16300075	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	50000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zitt3hEQHt7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zsghZJAtZTLc">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2023, and 2022, include impairment of intangible assets, valuation allowance for deferred tax asset, and non-cash equity transactions and stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15267	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13097	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2780682	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3397281	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2780682	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3397281	shares
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	31289	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	340231	usd
CY2022Q2	VICP	Nonrefundable Annual License Fee NonrefundableAnnualLicenseFee	10000	usd
CY2022Q1	us-gaap	Royalty Expense RoyaltyExpense	100000	usd
CY2023Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	83526	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	328571	shares
CY2023Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-01-27
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	363000	usd
CY2023Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	363000	usd
CY2023Q4	VICP	Debt Instrument Annual Principal Payment Debt Modification Debt Discount DebtInstrumentAnnualPrincipalPaymentDebtModificationDebtDiscount	33000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	5156	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	335156	usd
CY2022Q2	VICP	Nonrefundable Annual License Fee NonrefundableAnnualLicenseFee	10000	usd
CY2023Q4	VICP	Nonrefundable Annual Royalty NonrefundableAnnualRoyalty	100000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7440000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7440000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32071299	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31188460	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	400000	shares
CY2023Q2	us-gaap	Stock Issued1 StockIssued1	83526	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	100000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.50
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	54267	shares
CY2022Q3	VICP	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Capital Raise SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise	0.25
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0293	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1900000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.66
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y9M29D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	770000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.50
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2670000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.62
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M15D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2670000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.62
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M15D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2670000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.62
CY2023	VICP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y2M15D
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3548	usd
CY2021Q4	VICP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber	4060000	shares
CY2021Q4	VICP	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice	0.53
CY2022	VICP	Share Based Compensation Arrangement By Share Based Payment Award Weightedaverage Remaining Life Year Outstanding And Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedaverageRemainingLifeYearOutstandingAndExercisable	P1Y6M
CY2022	VICP	Stock Issued During Period Shares Stock Options Stock Issued During Period Shares Stock Options Expired StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExpired	3960000	shares
CY2022	VICP	Share Based Compensation Arrangements By Share Based Payment Award Nono Otions Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonoOtionsExpirationsInPeriodWeightedAverageExercisePrice	0.51
CY2022	VICP	Stock Issued During Period Shares Stock Options Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExercised	100000	shares
CY2022	VICP	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice	0.50
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	13953510	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	2033 to 2039
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	2930237	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1182112	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	984790	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-248244	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-206806	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	4346	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	22187	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	243898	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	184620	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2985572	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2741675	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2985572	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2741675	usd

Files In Submission

Name	View Source	Status
0001493152-24-041809-index-headers.html	Edgar Link	pending
0001493152-24-041809-index.html	Edgar Link	pending
0001493152-24-041809.txt	Edgar Link	pending
0001493152-24-041809-xbrl.zip	Edgar Link	pending
audit_001.jpg	Edgar Link	pending
audit_002.jpg	Edgar Link	pending
audit_003.jpg	Edgar Link	pending
audit_004.jpg	Edgar Link	pending
audit_005.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vicp-20231231.xsd	Edgar Link	pending
vicp-20231231_def.xml	Edgar Link	unprocessable
vicp-20231231_pre.xml	Edgar Link	unprocessable
vicp-20231231_lab.xml	Edgar Link	unprocessable
vicp-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Vicapsys Life Sciences Inc

2024 Q3 Form 10-K Financial Statement

#000149315224041809 Filed on October 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission